14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CFRX
Delisted

ContraFect Corporation Stock Price (Quote)

NASDAQ Stock Exchange > Healthcare > Biotechnology
Open Broker Account
$0.0500
+0 (+0%)
At Close: Mar 04, 2024
Forecast Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.0500 $0.0500 Monday, 4th Mar 2024 CFRX stock ended at $0.0500. During the day the stock fluctuated 0% from a day low at $0.0500 to a day high of $0.0500.
90 days $0.0457 $0.0620
52 weeks $0.0430 $3.95

Historical ContraFect Corporation prices

Date Open High Low Close Volume
Dec 19, 2022 $0.104 $0.108 $0.0992 $0.105 4 351 422
Dec 16, 2022 $0.105 $0.110 $0.0981 $0.107 2 199 721
Dec 15, 2022 $0.107 $0.112 $0.0977 $0.108 2 256 425
Dec 14, 2022 $0.100 $0.108 $0.0950 $0.107 3 400 815
Dec 13, 2022 $0.129 $0.130 $0.0884 $0.103 6 318 293
Dec 12, 2022 $0.120 $0.134 $0.118 $0.129 2 149 731
Dec 09, 2022 $0.130 $0.130 $0.122 $0.123 926 951
Dec 08, 2022 $0.130 $0.139 $0.125 $0.130 1 246 456
Dec 07, 2022 $0.136 $0.142 $0.125 $0.129 1 397 928
Dec 06, 2022 $0.163 $0.163 $0.135 $0.140 2 544 650
Dec 05, 2022 $0.149 $0.157 $0.141 $0.143 955 348
Dec 02, 2022 $0.160 $0.165 $0.148 $0.150 1 129 851
Dec 01, 2022 $0.170 $0.174 $0.152 $0.158 2 452 666
Nov 30, 2022 $0.151 $0.197 $0.148 $0.177 10 353 540
Nov 29, 2022 $0.153 $0.165 $0.142 $0.151 4 501 593
Nov 28, 2022 $0.160 $0.160 $0.135 $0.145 546 298
Nov 25, 2022 $0.145 $0.157 $0.138 $0.143 351 247
Nov 23, 2022 $0.160 $0.160 $0.141 $0.148 664 964
Nov 22, 2022 $0.133 $0.167 $0.133 $0.150 4 862 706
Nov 21, 2022 $0.130 $0.150 $0.130 $0.132 297 823
Nov 18, 2022 $0.148 $0.160 $0.143 $0.146 224 179
Nov 17, 2022 $0.150 $0.159 $0.141 $0.157 378 238
Nov 16, 2022 $0.150 $0.155 $0.141 $0.146 183 423
Nov 15, 2022 $0.143 $0.150 $0.143 $0.149 362 401
Nov 14, 2022 $0.140 $0.154 $0.140 $0.144 269 683
Click to get the best stock tips daily for free!

About ContraFect Corporation

ContraFect ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the in... CFRX Profile

Golden Star

Ticker Date Change Price
CVBF May 01 2.75% $16.75
FTSL May 01 0.282% $46.03
EQC Apr 30 0.694% $18.72
HRB Apr 30 0.635% $47.23
BSCQ Apr 30 0.576% $19.09
BSJP Apr 29 0.306% $22.91
LYG Apr 29 1.56% $2.56
ORA Apr 29 4.68% $64.48
DHT Apr 24 3.10% $11.28
LPLA Apr 19 3.12% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT